A possible explanation for this long term benefit of statins is that the triple negative (i.e. ER- PR-HER2-) breast cancers are generally more aggressive, have fewer available adjuvant systemic therapies, and have a higher risk of cancer recurrence within the first 5 years. This evidence concerns the gene ERBB2 and breast carcinoma.